Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD31xGPVI bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Tridek-One
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CD31xGPVI bispecific antibody is a first-in-class preclinical-stage bispecific antibody being developed by Tridek-One (a spin-off from INSERM) for the treatment of thromboinflammatory cardiovascular diseases, including ST-segment elevation myocardial infarction (STEMI), stroke, peripheral artery disease, and abdominal aortic aneurysm. Designed in an Fc-silent format, the antibody dual-targets the inhibitory immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor CD31 (PECAM-1) and the immunoreceptor tyrosine-based activation motif (ITAM)-containing platelet collagen receptor glycoprotein VI (GPVI). By agonizing CD31 and blocking GPVI, the therapeutic candidate inhibits collagen-driven platelet activation and aggregation, prevents platelet-leukocyte aggregate formation, and reduces NETosis, thereby providing both antithrombotic and anti-inflammatory efficacy while minimizing bleeding risks.
- Other names
- CD31/GPVI bispecific antibodyCD31×GPVI bispecific antibodyanti-CD31xGPVI bispecific antibodyanti-CD-31xGPVI bispecific antibodyanti-CD 31xGPVI bispecific antibody
02
Targets
PECAM1 (PECAM-1)
Beyond the preview
Go deeper on CD31xGPVI bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD31xGPVI bispecific antibody.